WO2017217796A1 - Inhibiteur de rhoa et son utilisation - Google Patents

Inhibiteur de rhoa et son utilisation Download PDF

Info

Publication number
WO2017217796A1
WO2017217796A1 PCT/KR2017/006281 KR2017006281W WO2017217796A1 WO 2017217796 A1 WO2017217796 A1 WO 2017217796A1 KR 2017006281 W KR2017006281 W KR 2017006281W WO 2017217796 A1 WO2017217796 A1 WO 2017217796A1
Authority
WO
WIPO (PCT)
Prior art keywords
rhoa
cancer
inhibitor
formula
group
Prior art date
Application number
PCT/KR2017/006281
Other languages
English (en)
Korean (ko)
Inventor
김연희
장혜령
남숭윤
정해림
Original Assignee
국립암센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 국립암센터 filed Critical 국립암센터
Publication of WO2017217796A1 publication Critical patent/WO2017217796A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Abstract

La présente invention concerne un inhibiteur de RhoA et son utilisation et, plus spécifiquement, un inhibiteur de RhoA représenté par la formule chimique (1) ou la formule chimique (2), une composition pour la prévention, l'amélioration ou le traitement du cancer de l'estomac, comprenant l'inhibiteur en tant qu'ingrédient actif, et une méthode de traitement du cancer utilisant l'inhibiteur de RhoA. L'inhibiteur de RhoA de la présente invention inhibe efficacement les cellules du cancer de l'estomac et se révèle donc efficace dans la prévention et le traitement du cancer de l'estomac. En outre, il n'a que peu d'effets secondaires, car il présente une toxicité inférieure à celle des médicaments anticancéreux.
PCT/KR2017/006281 2016-06-15 2017-06-15 Inhibiteur de rhoa et son utilisation WO2017217796A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0074746 2016-06-15
KR1020160074746A KR20170141542A (ko) 2016-06-15 2016-06-15 위암을 예방 및 치료하는 rhoa 억제제의 약학적 조성물

Publications (1)

Publication Number Publication Date
WO2017217796A1 true WO2017217796A1 (fr) 2017-12-21

Family

ID=60663484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/006281 WO2017217796A1 (fr) 2016-06-15 2017-06-15 Inhibiteur de rhoa et son utilisation

Country Status (2)

Country Link
KR (1) KR20170141542A (fr)
WO (1) WO2017217796A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109771415A (zh) * 2018-08-29 2019-05-21 湖北工业大学 一种含苯并间二氧杂环戊烯小分子抑制剂及在抑制鸟氨酸脱羧酶（odc）上的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102224059B1 (ko) * 2020-11-13 2021-03-08 한림대학교 산학협력단 RhoA 펩티드 억제제를 유효성분으로 함유하는 항암제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2039161A1 (es) * 1992-01-13 1993-08-16 Inst Investigacion Desarrollo Procedimiento de obtencion de nuevas hidrazonas con actividad antiproliferativa.
CN102786509A (zh) * 2011-05-16 2012-11-21 杭州民生药业有限公司 2-(5,6-二甲基呫吨酮-4-基)-乙酸的衍生物及其制备方法和用途
KR20140112489A (ko) * 2011-11-25 2014-09-23 유니베르시다데 페더랄 데 산타 카타리나 아실-하이드라존 및 옥사디아졸 화합물, 이를 포함하는 약학 조성물 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2039161A1 (es) * 1992-01-13 1993-08-16 Inst Investigacion Desarrollo Procedimiento de obtencion de nuevas hidrazonas con actividad antiproliferativa.
CN102786509A (zh) * 2011-05-16 2012-11-21 杭州民生药业有限公司 2-(5,6-二甲基呫吨酮-4-基)-乙酸的衍生物及其制备方法和用途
KR20140112489A (ko) * 2011-11-25 2014-09-23 유니베르시다데 페더랄 데 산타 카타리나 아실-하이드라존 및 옥사디아졸 화합물, 이를 포함하는 약학 조성물 및 이의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TOMIZAWA, H. ET AL.: "Antitumor Activities of Pyridine and Pyridone Derivatives", YAKUGAKU ZASSHI, vol. 86, no. 5, 1966, pages 433 - 437 *
WANG, Z. ET AL.: "Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening", JOURNAL OF CHEMICAL INFORMATION AND MODELING, vol. 49, no. 6, 15 May 2009 (2009-05-15), pages 1420 - 1427, XP009170439 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109771415A (zh) * 2018-08-29 2019-05-21 湖北工业大学 一种含苯并间二氧杂环戊烯小分子抑制剂及在抑制鸟氨酸脱羧酶（odc）上的应用

Also Published As

Publication number Publication date
KR20170141542A (ko) 2017-12-26

Similar Documents

Publication Publication Date Title
KR102061353B1 (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US9676749B2 (en) Compositions and methods for cancer detection and treatment
Pogorelcnik et al. Recent developments of DNA poisons-human DNA topoisomerase IIα inhibitors-as anticancer agents
US10647700B2 (en) EZH2 inhibitor and use thereof
JP2010031061A (ja) 多発性骨髄腫および他の癌の処置におけるＩκＢのインヒビターとしてのカルボリン誘導体
JP2009504192A (ja) ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
US8703736B2 (en) Therapeutic target for pancreatic cancer cells
JP2016525097A (ja) 黒色腫の治療のための組合せ医薬
AU2021333558B2 (en) Inhibitors of SARM1
CN109081808B (zh) 一类含有四氢异喹啉结构的酰基苯胺类化合物、用途及其制备方法
US20190160073A1 (en) Composition For Treating Or Preventing Liver Cancer
JP2022536518A (ja) Ｓａｒｍ１の阻害剤
JP2021504314A (ja) Ｍｙｓｔファミリーヒストンアセチルトランスフェラーゼ阻害剤
CA3163265A1 (fr) Inhibiteurs de sarm1
WO2017217796A1 (fr) Inhibiteur de rhoa et son utilisation
JP7478142B2 (ja) Ｓａｒｍ１阻害剤
WO2010062143A2 (fr) Composition anticancéreuse comprenant une substance et un agent antitumoraux et présentant des effets inhibiteurs sur l'activité et l'expression de l1cam
CN110357852B (zh) 苯并嘧啶类化合物、制备方法和用途
US9963701B2 (en) Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
Lai et al. Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease
WO2018105921A2 (fr) Utilisation d'une protéine à glissière à leucine pour diagnostiquer ou traiter la stéatose
Kalitin et al. A novel glycosylated indolocarbazole derivative LCS1269 effectively inhibits growth of human cancer cells in vitro and in vivo through driving of both apoptosis and senescence by inducing of DNA damage and modulating of AKT/mTOR/S6K and ERK pathways
JP7478252B2 (ja) Ｓａｒｍ１の阻害剤
JP6452954B2 (ja) 癌転移抑制剤
JP7477642B2 (ja) Ｓａｒｍ１の阻害剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17813619

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17813619

Country of ref document: EP

Kind code of ref document: A1